Several previous studies have suggested that the alpha-syn aggregates contribute to PD pathology is possible that is possible that an agent that inhibits and / or, even better, returns alpha-syn aggregation could eventually be used as a therapy for PD. Evidence that agents that interfere with alpha-syn aggregation could have positive effects in people with PD has now provided by a team of researchers ?? At the Ecole Polytechnique F Rale de Lausanne, Switzerland, and the University of Pennsylvania School of Medicine, Philadelphia, studied a rat model of the disease..
In the study it was found that a protein that yeast used order by protein aggregation , called Hsp104 protect, dramatically reduced both the formation of alpha-syn aggregates and the degeneration of neurons in the brain of a rat Mdoel of PD. In vitro studies have shown that not only prevent Hsp104 alpha-syn aggregate formation, but also interacted with mammalian proteins it them. The authors therefore suggest that Hsp104 can be strategy for the strategy for the treatment of patients with PD, for further studies on the safety of introducing Hsp104 into the brain..Earlier research shows the brain is medial temporal lobe has an major role in declarative memory – that is, recollection of facts and events and consequences. Past studies have shown that effect damage the MTL impairment in memory for the timing of of events within a sequence. Accurate declarative memory is is Alzheimer Alzheimer’s disease. However, little is about how individual structures within MTL remember information on known ‘what happens when ‘in a particular episode button events the order in which toasts on a wedding reception and that preceded the game winning hit on a baseball game.